TY - JOUR
T1 - The weak relationship between vitamin D compounds and glucose homeostasis measures in pregnant women with obesity : an exploratory sub-analysis of the DALI study
AU - Mendoza, Lilian Cristina
AU - Harreiter, Jürgen
AU - Desoye, Gernot
AU - Simmons, David
AU - Adelantado, Juan M.
AU - Kautzky-Willer, Alexandra
AU - Zawiejska, Agnieszka
AU - Wender-Ozegowska, Ewa
AU - Lapolla, Annunziata
AU - Dalfra, Maria G.
AU - Bertolotto, Alessandra
AU - Devlieger, Roland
AU - Dunne, Fidelma
AU - Mathiesen, Elisabeth R.
AU - Damm, Peter
AU - Andersen, Lisse Lotte
AU - Jensen, Dorte Moller
AU - Hill, David
AU - Poppel, Mireille Nicoline Maria van
AU - Corcoy, Rosa
PY - 2022
Y1 - 2022
N2 - Studies on the relationship between vitamin D (VitD) and glucose homeostasis usually consider either total VitD or 25OHD3 but not 25OHD2 and epimers. We aimed to evaluate the cross-sectional association of VitD compounds with glucose homeostasis measurements in pregnant women with overweight/obesity participating in the Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus Prevention study. Methods: The analysis included 912 women. Inclusion criteria: <20 weeks gestation, body mass index >= 29 kg/m(2) and information on exposure and outcome variables at baseline. Measurements: A 75 g OGTT at <20, 24-28 and 35-37 weeks gestation (except if previous diabetes diagnosis). Exposure variables: 25OHD2, 25OHD3 and C3-epimer. Outcome variables: fasting and post-challenge insulin sensitivity and secretion indices, corresponding disposition indices (DI), plasma glucose at fasting and 1 and 2 h, hyperglycemia in pregnancy (HiP). Statistics: Multivariate regression analyses with adjustment. Results: Baseline VitD sufficiency was 66.3%. Overall, VitD compounds did not show strong associations with any glucose homeostasis measures. 25OHD3 showed direct significant associations with: FPG at <20 and 24-28 weeks (standardized beta coefficient (beta) 0.124, p = 0.030 and 0.111, p = 0.026 respectively), 2 h plasma glucose at 24-28 weeks (beta 0.120, p = 0.018), and insulin sensitivity (1/HOMA-IR, beta 0.127, p = 0.027) at 35-37 weeks; it showed an inverse association with fasting DI (QUCKI*HOMA-beta) at <20 and 24-28 weeks (beta -0.124, p = 0.045 and beta -0.148, p = 0.004 respectively). 25OHD2 showed direct associations with post-challenge insulin sensitivity (Matsuda, beta 0.149, p = 0.048) at 24-28 weeks) and post-challenge DI (Matsuda*Stumvoll phase 1) at 24-28 and 35-37 weeks (beta 0.168, p = 0.030, beta 0.239, p = 0.006). No significant association with C3-epimer was observed at any time period. Conclusions: In these women with average baseline VitD in sufficiency range, VitD compounds did not show clear beneficial associations with glucose homeostasis measures.
AB - Studies on the relationship between vitamin D (VitD) and glucose homeostasis usually consider either total VitD or 25OHD3 but not 25OHD2 and epimers. We aimed to evaluate the cross-sectional association of VitD compounds with glucose homeostasis measurements in pregnant women with overweight/obesity participating in the Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus Prevention study. Methods: The analysis included 912 women. Inclusion criteria: <20 weeks gestation, body mass index >= 29 kg/m(2) and information on exposure and outcome variables at baseline. Measurements: A 75 g OGTT at <20, 24-28 and 35-37 weeks gestation (except if previous diabetes diagnosis). Exposure variables: 25OHD2, 25OHD3 and C3-epimer. Outcome variables: fasting and post-challenge insulin sensitivity and secretion indices, corresponding disposition indices (DI), plasma glucose at fasting and 1 and 2 h, hyperglycemia in pregnancy (HiP). Statistics: Multivariate regression analyses with adjustment. Results: Baseline VitD sufficiency was 66.3%. Overall, VitD compounds did not show strong associations with any glucose homeostasis measures. 25OHD3 showed direct significant associations with: FPG at <20 and 24-28 weeks (standardized beta coefficient (beta) 0.124, p = 0.030 and 0.111, p = 0.026 respectively), 2 h plasma glucose at 24-28 weeks (beta 0.120, p = 0.018), and insulin sensitivity (1/HOMA-IR, beta 0.127, p = 0.027) at 35-37 weeks; it showed an inverse association with fasting DI (QUCKI*HOMA-beta) at <20 and 24-28 weeks (beta -0.124, p = 0.045 and beta -0.148, p = 0.004 respectively). 25OHD2 showed direct associations with post-challenge insulin sensitivity (Matsuda, beta 0.149, p = 0.048) at 24-28 weeks) and post-challenge DI (Matsuda*Stumvoll phase 1) at 24-28 and 35-37 weeks (beta 0.168, p = 0.030, beta 0.239, p = 0.006). No significant association with C3-epimer was observed at any time period. Conclusions: In these women with average baseline VitD in sufficiency range, VitD compounds did not show clear beneficial associations with glucose homeostasis measures.
UR - https://hdl.handle.net/1959.7/uws:69556
U2 - 10.3390/nu14163256
DO - 10.3390/nu14163256
M3 - Article
SN - 2072-6643
VL - 14
JO - Nutrients
JF - Nutrients
IS - 16
M1 - 3256
ER -
